(Q43061662)

13 November 2017

title

Moxifloxacin: update and perspectives after 8 years of usage (English)

1 reference

13 November 2017

1 reference

Hartmut M Lode

1

1 reference

13 November 2017

Malina Schmidt-Ioanas

series ordinal

2

1 reference

13 November 2017

publication date

1 August 2008

1 reference

Expert Review of Respiratory Medicine

13 November 2017

published in

1 reference

13 November 2017

volume

2

1 reference

13 November 2017

issue

4

1 reference

13 November 2017

page(s)

443-453

1 reference

The quinolones: past, present, and future

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

DNA gyrase: an enzyme that introduces superhelical turns into DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Mechanism of action of nalidixic acid: Purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Mechanisms of resistance to quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Broader distribution of plasmid-mediated quinolone resistance in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Susceptibility to moxifloxacin of pneumococci isolated in English hospitals participating in the European Antimicrobial Resistance Surveillance System (EARSS) in 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Moxifloxacin in uncomplicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Moxifloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Efficacy and tolerability of moxifloxacin in patients with sinusitis treated in general practice : results of a post-marketing surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Clinical experience with moxifloxacin in patients with respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Guidelines for the management of adult lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

Eficacia clínica del moxifloxacino en el tratamiento de las agudizaciones de la bronquitis crónica. Revisión sistemática y metaanálisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.4.443

21 January 2018

Identifiers

DOI

10.1586/17476348.2.4.443

1 reference

13 November 2017

1 reference